Airway inflammation in mild intermittent and in persistent asthma.

PubWeight™: 1.69‹?› | Rank: Top 3%

🔗 View Article (PMID 9476850)

Published in Am J Respir Crit Care Med on February 01, 1998

Authors

A M Vignola1, P Chanez, A M Campbell, F Souques, B Lebel, I Enander, J Bousquet

Author Affiliations

1: INSERM U 454 and Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France.

Articles citing this

Airway remodeling in asthma. J Clin Invest (1999) 3.19

Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 2.74

Ultrastructural examination of bronchial biopsy specimens from children with moderate asthma. Thorax (2001) 1.85

A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J (2015) 1.82

A centennial history of research on asthma pathogenesis. Am J Respir Cell Mol Biol (2005) 1.72

Categorizing asthma severity: an overview of national guidelines. Clin Med Res (2004) 1.27

Role of hyaluronan and hyaluronan-binding proteins in human asthma. J Allergy Clin Immunol (2011) 1.19

Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax (2000) 1.17

Asthma drug adherence in a long term clinical trial. Arch Dis Child (2000) 1.16

Roles of apoptosis in airway epithelia. Am J Respir Cell Mol Biol (2006) 1.11

Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. J Exp Med (2006) 1.10

Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest (2010) 1.03

Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol (2003) 1.02

T cell directives for transcriptional regulation in asthma. Springer Semin Immunopathol (2003) 0.98

Interleukin-1beta mediates human airway epithelial cell migration via NF-kappaB. Am J Physiol Lung Cell Mol Physiol (2008) 0.98

Serotonin modulates the cytokine network in the lung: involvement of prostaglandin E2. Clin Exp Immunol (2007) 0.95

Current recommendations for the treatment of mild asthma. J Asthma Allergy (2010) 0.95

Relation of oxidant-antioxidant imbalance with disease progression in patients with asthma. Ann Thorac Med (2012) 0.93

Expression of naive/memory (CD45RA/CD45RO) markers by peripheral blood CD4+ and CD8 + T cells in children with asthma. Arch Immunol Ther Exp (Warsz) (2008) 0.87

Glucocorticoid and estrogen receptors are reduced in mitochondria of lung epithelial cells in asthma. PLoS One (2012) 0.85

Heat shock protein-27 protects human bronchial epithelial cells against oxidative stress-mediated apoptosis: possible implication in asthma. Cell Stress Chaperones (2002) 0.85

Apoptosis and the airway epithelium. J Allergy (Cairo) (2011) 0.85

Sputum hyaluronan and versican in severe eosinophilic asthma. Int Arch Allergy Immunol (2012) 0.84

Hyaluronan and Its Heavy Chain Modification in Asthma Severity and Experimental Asthma Exacerbation. J Biol Chem (2015) 0.84

Fas ligand expression on T cells is sufficient to prevent prolonged airway inflammation in a murine model of asthma. Am J Respir Cell Mol Biol (2009) 0.83

Autonomic modulations in patients with bronchial asthma based on short-term heart rate variability. Lung India (2012) 0.83

The therapeutic potential of Toll-like receptor 7 stimulation in asthma. Inflamm Allergy Drug Targets (2012) 0.83

Expression of IL-4/IL-13 receptors in differentiating human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2010) 0.80

BMI can influence adult males' and females' airway hyperresponsiveness differently. Multidiscip Respir Med (2012) 0.80

Effect of High, Medium, and Low Molecular Weight Hyaluronan on Inflammation and Oxidative Stress in an In Vitro Model of Human Nasal Epithelial Cells. Mediators Inflamm (2016) 0.80

The Rise and Fall of Hyaluronan in Respiratory Diseases. Int J Cell Biol (2015) 0.79

Airway mast cells in a rhesus model of childhood allergic airways disease. Toxicol Sci (2010) 0.79

A randomised controlled trial of small particle inhaled steroids in refractory eosinophilic asthma (SPIRA). Thorax (2015) 0.79

Abdominal aortic stiffness as a marker of atherosclerosis in childhood-onset asthma: a case-control study. Cardiovasc J Afr (2014) 0.79

Subepithelial Accumulation of Versican in a Cockroach Antigen-Induced Murine Model of Allergic Asthma. J Histochem Cytochem (2016) 0.78

Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells. J Clin Immunol (2004) 0.77

Relationship of circulating hyaluronic acid levels to disease control in asthma and asthmatic pregnancy. PLoS One (2014) 0.76

Fluticasone Induces Epithelial Injury and Alters Barrier Function in Normal Subjects. J Steroids Horm Sci (2014) 0.76

Corticosteroid administration reduces the concentration of hyaluronan in bronchoalveolar lavage in a murine model of eosinophilic airway inflammation. Inflamm Res (2012) 0.75

Interplay of extracellular matrix and leukocytes in lung inflammation. Cell Immunol (2016) 0.75

The role of measuring airway hyperresponsiveness and inflammatory biomarkers in asthma. Ther Clin Risk Manag (2005) 0.75

Pragmatic research and outcomes in asthma and COPD. Pragmat Obs Res (2012) 0.75

The effects of one-week fluticasone propionate inhalation therapy for Tc-99m DTPA radioaerosol distribution in asthma of children: a preliminary report. Lung (2003) 0.75

Articles by these authors

Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08

Eosinophilic inflammation in asthma. N Engl J Med (1990) 8.05

Over- and under-representation of short oligonucleotides in DNA sequences. Proc Natl Acad Sci U S A (1992) 5.55

A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy (2001) 5.07

A Single-Cell Analysis of the Transmission of Enzyme-Forming Capacity in Yeast. Proc Natl Acad Sci U S A (1951) 4.91

Compositional biases of bacterial genomes and evolutionary implications. J Bacteriol (1997) 4.85

Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J Immunol (1983) 4.51

Comparative DNA analysis across diverse genomes. Annu Rev Genet (1998) 3.67

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy (2005) 3.22

A new perspective on concepts of asthma severity and control. Eur Respir J (2008) 3.16

Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J (1999) 2.96

Induction of nitric oxide synthase in asthma. Lancet (1994) 2.93

Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J (2010) 2.77

Codon usages in different gene classes of the Escherichia coli genome. Mol Microbiol (1998) 2.73

OCULAR NEUROSIS. Br J Ophthalmol (1944) 2.71

Standards for practical allergen-specific immunotherapy. Allergy (2006) 2.70

Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med (1997) 2.47

Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med (2000) 2.36

Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med (1998) 2.36

Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34

Phylogeny of nitrogenase sequences in Frankia and other nitrogen-fixing microorganisms. J Mol Evol (1989) 2.33

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy (2007) 2.22

Genetic and biochemical characterization of the birA gene and its product: evidence for a direct role of biotin holoenzyme synthetase in repression of the biotin operon in Escherichia coli. J Mol Biol (1981) 2.14

Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy (2011) 2.13

TFIIF-TAF-RNA polymerase II connection. Genes Dev (1994) 2.10

Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med (2000) 2.08

Pro: Immunotherapy is clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med (2001) 2.04

The birA gene of Escherichia coli encodes a biotin holoenzyme synthetase. J Mol Biol (1981) 2.02

Statistical analyses of counts and distributions of restriction sites in DNA sequences. Nucleic Acids Res (1992) 1.99

Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy (2009) 1.97

Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol (1993) 1.91

Sputum induction. Eur Respir J Suppl (2002) 1.88

Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med (1997) 1.87

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy (2004) 1.84

Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med (2008) 1.82

Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J (2002) 1.79

Emergency treatment of allergic reactions to Hymenoptera stings. Clin Exp Allergy (1991) 1.76

Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy (2007) 1.75

Genome screen for asthma and related phenotypes in the French EGEA study. Am J Respir Crit Care Med (2000) 1.75

Upper airway x 1: allergic rhinitis and asthma: united disease through epithelial cells. Thorax (2009) 1.74

GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72

Rhinosinusitis in severe asthma. J Allergy Clin Immunol (2001) 1.72

Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy (2011) 1.71

A survey of the burden of allergic rhinitis in Europe. Allergy (2007) 1.71

Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J (2004) 1.70

Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70

Frequent exacerbators--a distinct phenotype of severe asthma. Clin Exp Allergy (2014) 1.69

Yeast Taf170 is encoded by MOT1 and exists in a TATA box-binding protein (TBP)-TBP-associated factor complex distinct from transcription factor IID. J Biol Chem (1994) 1.69

Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol (1999) 1.68

Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med (2012) 1.68

Similarities and dissimilarities of phage genomes. Proc Natl Acad Sci U S A (1996) 1.67

Measurement of the internal size of bronchi using high resolution computed tomography (HRCT) Eur Respir J (1994) 1.67

Chloroplast and nuclear gene sequences indicate late Pennsylvanian time for the last common ancestor of extant seed plants. Proc Natl Acad Sci U S A (1994) 1.66

Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy (2007) 1.63

Iatrogenic eosinophilic pleural effusion. Eur Respir Rev (2011) 1.63

Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy (2006) 1.62

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 1.61

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy (2005) 1.59

Identification and characterization of a TFIID-like multiprotein complex from Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1995) 1.56

Molecular evolution of angiosperm mitochondrial introns and exons. Proc Natl Acad Sci U S A (1997) 1.56

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy (2012) 1.55

Is bronchial hyperresponsiveness more frequent in women than in men? A population-based study. Am J Respir Crit Care Med (1997) 1.54

Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy (2013) 1.54

[Smoking habits, attitudes and knowledges of medical students of Medicine, Pharmacy and Odonto-Stomatology's Faculty of Dakar, Senegal]. Rev Mal Respir (2003) 1.54

Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem (1993) 1.53

Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol (1997) 1.53

Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy (2009) 1.53

Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem (1993) 1.53

Use of bio-lac fusion strains to study regulation of biotin biosynthesis in Escherichia coli. J Bacteriol (1980) 1.52

Motor neurone disease and exposure to lead. J Neurol Neurosurg Psychiatry (1970) 1.52

GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51

Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy (2000) 1.50

Update on severe asthma: what we know and what we need. Eur Respir Rev (2009) 1.50

Frequent oligonucleotides and peptides of the Haemophilus influenzae genome. Nucleic Acids Res (1996) 1.50

Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol (1999) 1.50

Precision of skin prick and puncture tests with nine methods. J Allergy Clin Immunol (1991) 1.50

Life-threatening food allergy in a child treated with FK506. J Pediatr Gastroenterol Nutr (1997) 1.49

Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ (2001) 1.48

Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45

Epidemiology of cypress pollen allergy in Montpellier. J Investig Allergol Clin Immunol (2012) 1.45

Bronchial brush biopsies for studies of epithelial inflammation in stable asthma and nonobstructive chronic bronchitis. Eur Respir J (1996) 1.45

Compliance in asthma. Respir Med (1999) 1.44

[Survival of the cementless Bousquet dual mobility cup: Minimum 15-year follow-up of 437 total hip arthroplasties]. Rev Chir Orthop Reparatrice Appar Mot (2008) 1.44

Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice. J Rheumatol (1997) 1.43

Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42

MAGIC Tool: integrated microarray data analysis. Bioinformatics (2005) 1.42

[Adult asthma exacerbations in questions]. Rev Mal Respir (2010) 1.40